Moderna (NASDAQ:MRNA) Director Abbas Hussain Sells 504 Shares

Moderna, Inc. (NASDAQ:MRNA) Director Abbas Hussain sold 504 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.60, for a total value of $13,910.40. Following the sale, the director owned 1,515 shares of the company’s stock, valued at approximately $41,814. This represents a 24.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Moderna Stock Performance

MRNA stock traded up $0.60 on Thursday, hitting $29.63. 8,167,573 shares of the company’s stock were exchanged, compared to its average volume of 10,866,739. The firm has a 50 day moving average price of $25.99 and a two-hundred day moving average price of $27.01. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $48.92. The stock has a market cap of $11.58 billion, a P/E ratio of -3.67 and a beta of 1.11.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $893.29 million. During the same period last year, the business posted $0.03 earnings per share. The firm’s revenue was down 45.4% compared to the same quarter last year. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Royal Bank Of Canada dropped their target price on shares of Moderna from $28.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Friday, November 21st. JPMorgan Chase & Co. cut their target price on Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research report on Thursday, October 23rd. Bank of America lowered their price target on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, November 10th. UBS Group reissued a “buy” rating on shares of Moderna in a report on Friday, November 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Reduce” and an average price target of $29.46.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Moderna by 3.2% in the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after purchasing an additional 1,312,192 shares during the period. Geode Capital Management LLC boosted its position in shares of Moderna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock valued at $244,458,000 after acquiring an additional 1,420,690 shares during the last quarter. Invesco Ltd. grew its stake in shares of Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after buying an additional 1,115,131 shares during the period. Theleme Partners LLP increased its stake in Moderna by 2.5% during the third quarter. Theleme Partners LLP now owns 8,068,810 shares of the company’s stock worth $208,417,000 after acquiring an additional 200,000 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Moderna by 0.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company’s stock worth $101,982,000 after purchasing an additional 11,270 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.